Johnson & Johnson said on Tuesday it would buy medical device maker V-Wave for up to $1.7 billion, the latest in a string of acquisitions aimed at driving growth once its blockbuster drug Stelara loses patent protection.
Tag Archive for: heart failure
With the late-stage win, Bayer announced that it plans to talk to regulators about seeking approval in an indication that is central to its $3 billion-plus peak sales forecast.
Trial results show Eli Lilly’s weight loss drug Zepbound reduces the risk of hospitalization, death and other outcomes for obese adults with a common type of heart failure, the company said on Thursday as it continues to build a case for the medication’s wider health benefits.
Cardior is a leader in the discovery and development of therapies that target RNA as a means to prevent, repair and reverse diseases of the heart. The company’s therapeutic approach targets distinctive non-coding RNAs as a platform for addressing root causes of cardiac dysfunctions with an aim to achieve lasting patient impact.
Novo Nordisk notched another win Friday as its mega blockbuster Wegovy (semaglutide) proved to also help patients with a common type of heart failure. The Danish pharma company announced results from a Phase III trial, published in The New England Journal of Medicine, adding to the drug’s growing list of benefits.
The drug, acoramidis, is being developed to treat a rare disease that can lead to heart failure.
The FDA has approved Lexicon Pharmaceuticals’ sotagliflozin, now to be marketed as Inpefa, as a once-daily oral medication to cut the risk of cardiovascular death and heart failure admissions and visits in adult patients with underlying heart failure, the company announced Friday.
Citing lack of efficacy evidence, the FDA rejected Cytokinetics’ heart failure hopeful omecamtiv mecarbil in a Tuesday evening decision.
A peer-reviewed study published in Journal of Clinical Medicine validates the use of Biobeat’s wrist monitor for advanced noninvasive hemodynamic monitoring in HF patients.
Today AstraZeneca won European endorsement for its blockbuster drug, dapagliflozin, as a treatment for all forms of heart failure.